Veritas Genetics Launches Collaboration with Mayo Clinic to Integrate Whole Genome Sequencing into Clinical Care
Goal is to empower physicians and patients through making whole genome sequencing broadly available
BOSTON, Jan. 8, 2018— Veritas Genetics, The Genome Company, and Mayo Clinic are entering into an agreement to make whole genome sequencing broadly available to healthy individuals.
As part of this collaboration:
- The team at Mayo Clinic’s Center for Individualized Medicine will provide medical and clinical expertise to the Veritas team.
- Veritas will integrate Mayo Clinic’s know-how into its flagship product myGenome.
- Patients who qualify for a Mayo Clinic research study of healthy adults will be offered Veritas myGenome screening test for whole genome sequencing.
- Mayo Clinic will become a shareholder of Veritas.
“The Center for Individualized Medicine at Mayo Clinic is the gold standard in personalized medicine and we are proud and honored to collaborate with such a professional and dedicated team. This is a great step to further realize the promise of the human genome,” expressed Mirza Cifric, Founder, CEO Veritas Genetics. [Read more…]
Cordlife Becomes Cord Blood Market Leader in Hong Kong with Acquisition of HealthBaby
Continues trend of cord blood industry consolidation on a global basis
SINGAPORE, 3 January 2018 – Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”) has signed a sale and purchase agreement to acquire full control of HealthBaby Biotech (Hong Kong) Co., Limited (“HealthBaby Hong Kong”), in a move that will expand its presence in the private cord blood banking industry in Hong Kong and Macau. [Read more…]
2017 Marks the 1st Year That Regenerative Medicine Disrupted Healthcare
The regenerative medicine industry has been rapidly expanding over the past few years, making it a high-value, fast-growth market. Key drivers for the market include high rates of clinical trials, accelerated pathways for product approvals, new technologies to support cell and gene therapy manufacturing, and the potential for cell therapies to revolutionize healthcare.
The regenerative medicine market gained major momentum when the Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T cell therapy in the U.S. in August 2017 (Kymriah). In October 2017, Kite Pharma became the second company to get FDA approval of a CAR-T cell therapy (Yescarta).
With swelling momentum to support the CAR-T technology, there are now close to 40 companies developing redirected T cells or NK cells for therapeutic use. [Read more…]
Japan’s Laws Supporting Accelerated Pathways for Cell Therapies
In late 2014, Japan passed two new laws that revolutionized the commercialization of cell therapies within the country by providing an accelerated pathway for product approvals. While there has been much discussion about these laws, few people have a clear understanding of the implications of these regulations on a global scale.
Below, we summarize the laws, identify their importance, and most importantly, speak to how Japan has become a “gateway country” for regenerative medicines. [Read more…]
- « Previous Page
- 1
- …
- 246
- 247
- 248
- 249
- 250
- …
- 338
- Next Page »